Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes
Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer’s disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, revers...
Main Authors: | Stane Pajk, Damijan Knez, Urban Košak, Maja Zorović, Xavier Brazzolotto, Nicolas Coquelle, Florian Nachon, Jacques-Philippe Colletier, Marko Živin, Jure Stojan, Stanislav Gobec |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2019.1710502 |
Similar Items
-
4-Phenethyl-1-Propargylpiperidine-Derived Dual Inhibitors of Butyrylcholinesterase and Monoamine Oxidase B
by: Tjaša Mazej, et al.
Published: (2021-07-01) -
Bacterial Expression of Human Butyrylcholinesterase as a Tool for Nerve Agent Bioscavengers Development
by: Xavier Brazzolotto, et al.
Published: (2017-10-01) -
Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study
by: Terrone L. Rosenberry, et al.
Published: (2017-11-01) -
Leufolins A and B, Potent Butyrylcholinesterase-inhibiting Flavonoid Glucosides from Leucas urticifolia
by: Sher Bahadar Khan, et al.
Published: (2007-07-01) -
The role of butyrylcholinesterase in the pathogenesis of Alzheimer's disease
by: Hao WU, et al.
Published: (2017-12-01)